Clinical
CCS1477 in patients
CellCentric’s first-in-class p300/CBP inhibitor is in patients with advanced, drug-resistant prostate cancer, as well as in patients with haematological malignancies (multiple myeloma, AML, lymphomas). CCS1477 will also be used to target tumours with specific drivers (p300 or CBP mutations, AR+, MYC over-expression). This includes small cell lung, bladder and breast cancers.
Patient enrolment
Potential suitability for enrolment in a CCS1477 clinical trial will be made by oncologists at our participating hospitals, and not by CellCentric. Any advice on clinical study options should come from your general practitioner and/or oncologist.
Study CCS1477-01
A Phase 1b/2a clinical trial is underway with Prof Johann de Bono, ICR/Royal Marsden Hospital, as Chief Investigator, primarily recruiting heavily pre-treated, late stage prostate cancer patients, those that are resistant to existing standard of care treatments. Multiple other sites are also active across the UK, with expansion to follow into the US, including the Kimmel Cancer Center, TJU Philadelphia.
The initial phase is testing different doses and schedules of CCS1477, assessing tolerability, pharmacokinetics and initial biological effects. This will be followed by expansion into defined cohorts of patients, with CCS1477 being administered on its own or in combination with one of either Xtandi (enzalutamide) or Zytiga (abiraterone).
In addition, CCS1477 will also be tested iin patients with tumours with specific drivers; p300 or CBP gene mutations as well as those tumours that are AR+ or over-expressing MYC.
The initial phase is testing different doses and schedules of CCS1477, assessing tolerability, pharmacokinetics and initial biological effects. This will be followed by expansion into defined cohorts of patients, with CCS1477 being administered on its own or in combination with one of either Xtandi (enzalutamide) or Zytiga (abiraterone).
In addition, CCS1477 will also be tested iin patients with tumours with specific drivers; p300 or CBP gene mutations as well as those tumours that are AR+ or over-expressing MYC.
Study CCS1477-02
A Phase 1b/2a multi-centre, multi-part study is evaluating CCS1477 as a monotherapy in patients with multiple myeloma, acute myeloid leukaemia (AML) and non-Hodgkin lymphoma (NHL). This is being led by Prof Tim Somervaille of the Christie Hospital, Manchester. Patient recruitment is now open across the UK, with expansion into the US to follow.
As with study CCS1477-01, once a monotherapy dose and schedule is established, CCS1477 will be tested with existing agents, such as in combination with pomalidomide for multiple myeloma.
As with study CCS1477-01, once a monotherapy dose and schedule is established, CCS1477 will be tested with existing agents, such as in combination with pomalidomide for multiple myeloma.
Related Links